Leukemia & Lymphoma最新文献

Cytarabine as a salvage mobilization strategy after failure of cyclophosphamide-based stem cell collection for Daratumumab-treated multiple myeloma patients. 阿糖胞苷作为达拉图单抗治疗的多发性骨髓瘤患者在环磷酰胺干细胞收集失败后的救助动员策略。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-05-08 DOI: 10.1080/10428194.2026.2666848

Tommaso Perini, Alessia Orsini, Francesca Farina, Valeria Ferla, Raffaella Milani, Sarah Marktel, Luca Canziani, Rossella Gammino, Daniele Sannipoli, Filippo Magri, Rosamaria Nitti, Milena Coppola, Sara Mastaglio, Magda Marcatti, Fabio Ciceri

引用次数: 0

Predictors of acute kidney injury following the first cycle of high-dose methotrexate in patients with hematological malignancies. 血液恶性肿瘤患者高剂量甲氨蝶呤第一周期后急性肾损伤的预测因素。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-05-05 DOI: 10.1080/10428194.2026.2666843

Nour Faqeer, Haya Kasabi, Jude Aqarbeh, Farah Ghananim, Mohammad Makoseh

引用次数: 0

Impact of time-to-antibiotics on hospital mortality in patients with hematological malignancies and febrile neutropenia: a single center propensity score matching analysis. 使用抗生素时间对血液恶性肿瘤和发热性中性粒细胞减少患者住院死亡率的影响：单中心倾向评分匹配分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-05-05 DOI: 10.1080/10428194.2026.2666849

Andry Van de Louw, Megan Kang, Daniel Guck, Myles Nickolich

引用次数: 0

Single dose antithymocyte globulin effectively reduces GVHD and improves survival in patient undergoing myeloablative matched sibling alloHCT. 单剂量抗胸腺细胞球蛋白可有效降低GVHD并提高接受清骨髓匹配同胞同种异体造血干细胞移植患者的生存率。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-05-05 DOI: 10.1080/10428194.2026.2666845

Anmol Baranwal, Jacqueline Baptista, Anu Kadanagowd, Kristy Luke, Halle Cheplowitz, Sunita Nathan, Celalettin Ustun

引用次数: 0

Ten-day venetoclax plus fluconazole with azacitidine or low-dose cytarabine for elderly/unfit AML patients in resource-limited settings. 在资源有限的情况下，10天venetoclax加氟康唑联合阿扎胞苷或低剂量阿糖胞苷治疗老年/不适合急性髓性白血病患者。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-05-04 DOI: 10.1080/10428194.2026.2665794

Rory Bennett, Tom Sapsford, Manjula Deo, Anna Elinder-Camburn, Merit Hanna, Sophie Leitch, Debbie Moore, Priya Nandani, Denis O'Keeffe, Rebecca Powell, Natalie Stockx, Eileen Merriman

引用次数: 0

CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma. CD47：复发/难治性恶性淋巴瘤免疫治疗的一个有希望的靶点

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-29 DOI: 10.1080/10428194.2026.2661769

Shuzhen Xiong, Ningning Yue, Shuni Zhang, Yu Xu, Jiajia Cao, Xinyang Liu, Chongyang Wu

{"title":"CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma.","authors":"Shuzhen Xiong, Ningning Yue, Shuni Zhang, Yu Xu, Jiajia Cao, Xinyang Liu, Chongyang Wu","doi":"10.1080/10428194.2026.2661769","DOIUrl":"https://doi.org/10.1080/10428194.2026.2661769","url":null,"abstract":"CD47 is an immune checkpoint molecule widely expressed on various cell types and has emerged as a key target in cancer immunotherapy due to its role in mediating tumor immune escape via the 'don't eat me' signal. In lymphoma, CD47 expression shows heterogeneity across subtypes, with elevated levels closely linked to poor prognosis. Mechanistically, CD47 blockade exerts dual effects: on one hand, it relieves the inhibition of macrophage phagocytosis via the CD47/SIRPα pathway, thereby enhancing tumor clearance; on the other hand, it may also disrupt CD47-mediated signaling pathways involving thrombospondin-1 (TSP-1) and integrins, thus exerting multifaceted anti-tumor effects. Although CD47-targeting approaches face clinical challenges like off-target toxicity and transient responses, emerging strategies combining CD47 inhibition with other therapies or utilizing gene editing show promise for overcoming resistance. By integrating evidence on CD47 expression and mechanisms, this review assesses its therapeutic potential in lymphoma to guide future clinical applications.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-21"},"PeriodicalIF":2.2,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathologic features of lymphoma-associated hemophagocytic lymphohistiocytosis in a multicenter adult cohort. 多中心成人队列淋巴瘤相关噬血细胞淋巴组织细胞增多症的临床病理特征

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-29 DOI: 10.1080/10428194.2026.2663069

Kelly Meza-Capcha, Mitchell Boshkos, Humberto Nieves Jimenez, Carla Romagnoli, Leily Santos, Alexandra Lyubimova, Jacqueline Barrientos, Martha Mims

{"title":"Clinicopathologic features of lymphoma-associated hemophagocytic lymphohistiocytosis in a multicenter adult cohort.","authors":"Kelly Meza-Capcha, Mitchell Boshkos, Humberto Nieves Jimenez, Carla Romagnoli, Leily Santos, Alexandra Lyubimova, Jacqueline Barrientos, Martha Mims","doi":"10.1080/10428194.2026.2663069","DOIUrl":"https://doi.org/10.1080/10428194.2026.2663069","url":null,"abstract":"Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that, in adults, is most commonly secondary to malignancy. Lymphoma-associated HLH (LA-HLH) is typically driven by aggressive non-Hodgkin lymphomas, while Hodgkin lymphoma is reported infrequently. We conducted a retrospective, multicenter analysis of adults diagnosed with LA-HLH between 2000 and 2024 at two tertiary academic centers. HLH diagnoses were confirmed using HLH-2004 criteria, and clinicopathologic features, laboratory findings, and outcomes were analyzed descriptively, with stratification by HIV status. Among 20 patients with LA-HLH, Hodgkin lymphoma accounted for 60% of cases. HIV-positive patients more commonly developed aggressive non-Hodgkin lymphomas with severe systemic inflammation, whereas HIV-negative patients more frequently had Hodgkin lymphoma. Soluble interleukin-2 receptor levels were uniformly elevated among evaluable patients. Overall mortality remained high. These findings are descriptive and hypothesis-generating and highlight the clinical heterogeneity of LA-HLH.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023). 揭示CAR - t细胞治疗大b细胞淋巴瘤的护理途径：来自法国一项全国性研究（2018-2023）的见解。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-29 DOI: 10.1080/10428194.2026.2652533

C Thieblemont, D Caillot, Morgane Pierre, S Branchoux, H Lemasson, A Caron, C Nevoret, E Torreton, A Petel, F Despas

{"title":"Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).","authors":"C Thieblemont, D Caillot, Morgane Pierre, S Branchoux, H Lemasson, A Caron, C Nevoret, E Torreton, A Petel, F Despas","doi":"10.1080/10428194.2026.2652533","DOIUrl":"https://doi.org/10.1080/10428194.2026.2652533","url":null,"abstract":"This study describes the inpatient care pathway for 1914 Large B-cell Lymphoma (LBCL) patients treated with CAR T-cell therapy in France between 2018 and 2023 and identifies factors influencing their management. Based on a retrospective analysis of the French national hospital database, we found the average CAR T-cell infusion stay was shorter for patients in the second line of treatment versus later lines (20.4 vs. 23.8 days). The specific product used was also influential; for example, lisocabtagene maraleucel was associated with shorter stays and fewer ICU admissions than axicabtagene ciloleucel. A multivariate analysis confirmed that while patient characteristics and the CAR T-cell product influenced outcomes, higher center experience was a primary determinant. More experienced centers had shorter hospital stays and a higher probability of patients being discharged home, demonstrating that the management of CAR T-cell patients is largely dependent on institutional experience.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy may be omitted in children and adolescents with classical Hodgkin lymphoma in complete remission after frontline risk and response-adapted chemotherapy: a multicenter clinical trial (LH-GALOP 2017). 一项多中心临床试验（LH-GALOP 2017）显示，在一线风险和反应性化疗后完全缓解的经典霍奇金淋巴瘤儿童和青少年患者可以省略放疗。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-28 DOI: 10.1080/10428194.2026.2662496

Elizabeth Alfaro, Magdalena Schelotto, Hernán Zamaro, Cristian Sánchez La Rosa, Myriam Guitter, Carolina Romero, Laura Galluzzo, Natalia Pinto, Luisina Peruzzo, Carolina Pages, Florencia Nuñez, Carla Pennella, Emma Concha, Elizabeth Tedesco, Agustín Dabezies, Luis Castillo, María Sara Felice, Pedro Zubizarreta

{"title":"Radiotherapy may be omitted in children and adolescents with classical Hodgkin lymphoma in complete remission after frontline risk and response-adapted chemotherapy: a multicenter clinical trial (LH-GALOP 2017).","authors":"Elizabeth Alfaro, Magdalena Schelotto, Hernán Zamaro, Cristian Sánchez La Rosa, Myriam Guitter, Carolina Romero, Laura Galluzzo, Natalia Pinto, Luisina Peruzzo, Carolina Pages, Florencia Nuñez, Carla Pennella, Emma Concha, Elizabeth Tedesco, Agustín Dabezies, Luis Castillo, María Sara Felice, Pedro Zubizarreta","doi":"10.1080/10428194.2026.2662496","DOIUrl":"https://doi.org/10.1080/10428194.2026.2662496","url":null,"abstract":"A multicentre, prospective, risk and response adapted treatment for newly diagnosed paediatric classical Hodgkin Lymphoma was carried out to avoid radiotherapy (RT) when complete remission (CR) was achieved after chemotherapy. Three risk groups were initially defined. Chemotherapy combined ABVD and ESHAP regimes. CR was defined by Deauville Score <1-2 or >80% CT volume reduction. Patients in CR after completing chemotherapy did not receive RT, those in partial remission received involved site RT (30 Gy). Refractory disease was considered a trial failure. From October 2017 to November 2024, 109 assessable patients were recruited, M/F = 1.8, median age 11.9 (r = 3-16.8) years. Low risk = 18%, Intermediate risk = 30%, High risk = 51%. CR after chemotherapy was obtained in 94 patients (86.2%). Radiotherapy was delivered in 19.3% of patients, including cases in partial remission, relapse, and refractory disease. With a median follow up of 58 months, at 5 years, EFSp was 88.5% (SE = 3%) and OS, 100%.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine. 靶向IL-8轴治疗高危骨髓增生异常综合征：抗体阻断联合地西他滨/cedazuridine的临床经验

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-28 DOI: 10.1080/10428194.2026.2661078

Alain Mina, Katherine R Calvo, Katherine McKinnon, Ayush T Raman, Weixin Wang, Lea Cunningham, Yi Liu, Rebecca Alexander, Daniel R Larson, Steven Pavletic, Kathy L McGraw

{"title":"Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine.","authors":"Alain Mina, Katherine R Calvo, Katherine McKinnon, Ayush T Raman, Weixin Wang, Lea Cunningham, Yi Liu, Rebecca Alexander, Daniel R Larson, Steven Pavletic, Kathy L McGraw","doi":"10.1080/10428194.2026.2661078","DOIUrl":"https://doi.org/10.1080/10428194.2026.2661078","url":null,"abstract":"Clinical and laboratory findings are presented from a 64-year-old female with myelodysplastic syndrome and increased blasts-2 (MDS-IB2) from Phase I/II trial evaluating the anti-IL8 antibody, BMS-986253, in combination with oral decitabine/cedazuridine (NCT05148234). Each 28-day cycle included BMS-986253 1200 mg IV on Day 1 and 15, and oral decitabine/cedazuridine (35 mg/100 mg) on Days 2-7. The patient received 2.5 cycles. Treatment was discontinued on Cycle 3 Day 8 after development of jaw osteonecrosis, deemed unlikely to be treatment related. Despite presenting with high-risk disease, the patient achieved stable disease. Serial bone marrow assessments revealed decreased granulocytes, increased lymphocytes, and reduced CD45 + CD33 + HLA-DR- and CD117 + HLA-DR- cells. Bone marrow plasma multiplex cytokine analysis demonstrated increased inflammatory and immune surveillance proteins. Optical genome mapping identified ETS-related gene, ERG, somatic duplication with post-treatment decreased variant allele frequency. Post-treatment molecular changes with clinical disease stability, suggest IL-8 pathway inhibition biological activity after even short duration.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0